Tags

Type your tag names separated by a space and hit enter

Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells.
Front Immunol. 2020; 11:1372.FI

Abstract

Current guidelines for COVID-19 management recommend the utilization of various repurposed drugs. Despite ongoing research toward the development of a vaccine against SARS-CoV-2, such a vaccine will not be available in time to contribute to the containment of the ongoing pandemic. Therefore, there is an urgent need to develop a framework for the rapid identification of novel targets for diagnostic and therapeutic interventions. We analyzed publicly available transcriptomic datasets of SARS-CoV infected humans and mammals to identify consistent differentially expressed genes then validated in SARS-CoV-2 infected epithelial cells transcriptomic datasets. Comprehensive toxicogenomic analysis of the identified genes to identify possible interactions with clinically proven drugs was carried out. We identified IFITM3 as an early upregulated gene, and valproic acid was found to enhance its mRNA expression as well as induce its antiviral action. These findings indicate that analysis of publicly available transcriptomic and toxicogenomic data represents a rapid approach for the identification of novel targets and molecules that can modify the action of such targets during the early phases of emerging infections like COVID-19.

Authors+Show Affiliations

Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates. Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, QC, Canada.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32595654

Citation

Hachim, Mahmood Yaseen, et al. "Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells." Frontiers in Immunology, vol. 11, 2020, p. 1372.
Hachim MY, Al Heialy S, Hachim IY, et al. Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. Front Immunol. 2020;11:1372.
Hachim, M. Y., Al Heialy, S., Hachim, I. Y., Halwani, R., Senok, A. C., Maghazachi, A. A., & Hamid, Q. (2020). Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. Frontiers in Immunology, 11, 1372. https://doi.org/10.3389/fimmu.2020.01372
Hachim MY, et al. Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. Front Immunol. 2020;11:1372. PubMed PMID: 32595654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interferon-Induced Transmembrane Protein (IFITM3) Is Upregulated Explicitly in SARS-CoV-2 Infected Lung Epithelial Cells. AU - Hachim,Mahmood Yaseen, AU - Al Heialy,Saba, AU - Hachim,Ibrahim Yaseen, AU - Halwani,Rabih, AU - Senok,Abiola C, AU - Maghazachi,Azzam A, AU - Hamid,Qutayba, Y1 - 2020/06/10/ PY - 2020/04/16/received PY - 2020/05/28/accepted PY - 2020/6/30/entrez PY - 2020/7/1/pubmed PY - 2020/7/3/medline KW - COVID-19 KW - SARS-CoV-2 KW - antiviral immunity KW - interferon-induced transmembrane proteins KW - valproic acid SP - 1372 EP - 1372 JF - Frontiers in immunology JO - Front Immunol VL - 11 N2 - Current guidelines for COVID-19 management recommend the utilization of various repurposed drugs. Despite ongoing research toward the development of a vaccine against SARS-CoV-2, such a vaccine will not be available in time to contribute to the containment of the ongoing pandemic. Therefore, there is an urgent need to develop a framework for the rapid identification of novel targets for diagnostic and therapeutic interventions. We analyzed publicly available transcriptomic datasets of SARS-CoV infected humans and mammals to identify consistent differentially expressed genes then validated in SARS-CoV-2 infected epithelial cells transcriptomic datasets. Comprehensive toxicogenomic analysis of the identified genes to identify possible interactions with clinically proven drugs was carried out. We identified IFITM3 as an early upregulated gene, and valproic acid was found to enhance its mRNA expression as well as induce its antiviral action. These findings indicate that analysis of publicly available transcriptomic and toxicogenomic data represents a rapid approach for the identification of novel targets and molecules that can modify the action of such targets during the early phases of emerging infections like COVID-19. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/32595654/Interferon_Induced_Transmembrane_Protein__IFITM3__Is_Upregulated_Explicitly_in_SARS_CoV_2_Infected_Lung_Epithelial_Cells_ L2 - https://doi.org/10.3389/fimmu.2020.01372 DB - PRIME DP - Unbound Medicine ER -